JANX Janux Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: JANX

Price (delayed)

$48.015

Market cap

$2.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.32

Enterprise value

$2.48B

Highlights
The quick ratio is up by 33% year-on-year and by 9% since the previous quarter
The EPS has grown by 13% YoY and by 11% from the previous quarter
JANX's gross profit is down by 6% YoY and by 4.5% QoQ
The revenue has contracted by 6% YoY and by 4.5% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of JANX
Market
Shares outstanding
51.66M
Market cap
$2.48B
Enterprise value
$2.48B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.44
Price to sales (P/S)
261.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
307.43
Earnings
Revenue
$8.08M
EBIT
-$58.29M
EBITDA
-$56.34M
Free cash flow
-$52.43M
Per share
EPS
-$1.32
Free cash flow per share
-$1.19
Book value per share
$7.46
Revenue per share
$0.18
TBVPS
$8.64
Balance sheet
Total assets
$380.41M
Total liabilities
$36.06M
Debt
$24.54M
Equity
$344.35M
Working capital
$336.21M
Liquidity
Debt to equity
0.07
Current ratio
26.8
Quick ratio
26.46
Net debt/EBITDA
-0.08
Margins
EBITDA margin
-697%
Gross margin
100%
Net margin
-721.2%
Operating margin
-902.9%
Efficiency
Return on assets
-16%
Return on equity
-17.9%
Return on invested capital
-16.7%
Return on capital employed
-15.9%
Return on sales
-721.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

JANX stock price

How has the Janux Therapeutics stock price performed over time
Intraday
-3.55%
1 week
0.11%
1 month
21.46%
1 year
219.25%
YTD
347.48%
QTD
27.53%

Financial performance

How have Janux Therapeutics's revenue and profit performed over time
Revenue
$8.08M
Gross profit
$8.08M
Operating income
-$72.98M
Net income
-$58.29M
Gross margin
100%
Net margin
-721.2%
The operating margin has contracted by 16% YoY
JANX's operating income is down by 9% year-on-year but it is up by 2.8% since the previous quarter
The net income has grown by 8% YoY and by 7% from the previous quarter
JANX's gross profit is down by 6% YoY and by 4.5% QoQ

Growth

What is Janux Therapeutics's growth rate over time

Valuation

What is Janux Therapeutics stock price valuation
P/E
N/A
P/B
6.44
P/S
261.47
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
307.43
The EPS has grown by 13% YoY and by 11% from the previous quarter
JANX's equity is up by 7% year-on-year
The revenue has contracted by 6% YoY and by 4.5% from the previous quarter

Efficiency

How efficient is Janux Therapeutics business performance
The return on invested capital is up by 16% year-on-year and by 10% since the previous quarter
JANX's return on equity is up by 9% since the previous quarter and by 4.3% year-on-year
The ROA has grown by 8% from the previous quarter and by 5% YoY
The ROS has grown by 2.4% from the previous quarter

Dividends

What is JANX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for JANX.

Financial health

How did Janux Therapeutics financials performed over time
The current ratio has grown by 33% YoY and by 9% from the previous quarter
The quick ratio is up by 33% year-on-year and by 9% since the previous quarter
Janux Therapeutics's debt is 93% lower than its equity
Janux Therapeutics's debt to equity has decreased by 13% YoY
JANX's equity is up by 7% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.